Not exact matches
AMP T2D focuses on type 2 diabetes genetics, seeking to use and supplement the substantial amount of human genetic data available from people with type 2 diabetes, or
at risk of developing it, to
identify and validate
novel molecules and pathways as
targets for
therapeutic development.
Floryne Buishand, 30, from the Netherlands, is a postdoctoral researcher
at the National Cancer Institute / NIH, Bethesda, USA, studies genomic changes associated with endocrine cancers with the ultimate goal of
identifying novel diagnostic and prognostic markers, as well as
novel therapeutic targets.
We are looking
at the role of complement proteins in inflammatory diseases such as atherosclerosis, to
identify novel therapeutic targets.
Two new precision medicine tests that look beyond cancer genes to
identify novel therapeutic targets have just received New York State Department of Health approval and are now available to both oncologists and cancer researchers for use
at the front lines of patient care.